Valentina Pan

Valentina Pan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2019 in Cells
Verified
Journal Article
Open access
PDF file
MKMarina Khodanovich
Marina Khodanovich
APAnna Prokopchuk
Anna Prokopchuk
VPValentina Pan
Valentina Pan
EPEdgar Pan
Edgar Pan
AAAndrey Akulov
Andrey Akulov
VYVasily L. Yarnykh
Vasily L. Yarnykh
Macromolecular proton fraction (MPF) has been established as a quantitative clinically-targeted MRI myelin biomarker based on recent demyelination studies. This study aimed to assess the capability of MPF to quantify remyelination using the murine cuprizone-induced reversible demyelination model. MPF was measured in vivo using the fast single-point method in three animal groups (control, cuprizone-induced demyelination, and remyelination after cuprizone withdrawal) and compared to quantitative immunohistochemistry for myelin basic protein (MBP), myelinating oligodendrocytes (CNP-positive cells), and oligodendrocyte precursor cells (OPC, NG2-positive cells) in the corpus callosum, caudate putamen, hippocampus, and cortex. In the demyelination group, MPF, MBP-stained area, and oligodendrocyte count were significantly reduced, while OPC count was significantly increased as compared to both control and remyelination groups in all anatomic structures (p < 0.05). All variables were similar in the control and remyelination groups. MPF and MBP-stained area strongly correlated in each anatomic structure (Pearson’s correlation coefficients, r = 0.80–0.90, p < 0.001). MPF and MBP correlated positively with oligodendrocyte count (r = 0.70–0.84, p < 0.01 for MPF; r = 0.81–0.92, p < 0.001 for MBP) and negatively with OPC count (r = −0.69–−0.77, p < 0.01 for MPF; r = −0.72–−0.89, p < 0.01 for MBP). This study provides immunohistological validation of fast MPF mapping as a non-invasive tool for quantitative assessment of de- and remyelination in white and gray matter and indicates the feasibility of using MPF as a surrogate marker of reparative processes in demyelinating diseases.

13 December 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
VSVictoria Skurikhina
Victoria Skurikhina
EPEdgar Pan
Edgar Pan
MZMariia Zhukova
Mariia Zhukova
IZIrina Zharkikh
Irina Zharkikh
ADAlexander Dygai
Alexander Dygai
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.

9 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
VSVictoria Skurikhina
Victoria Skurikhina
EPEdgar Pan
Edgar Pan
MZMariia Zhukova
Mariia Zhukova
IZIrina Zharkikh
Irina Zharkikh
ADAlexander Dygai
Alexander Dygai
Background/Objectives: Neuroinflammation is a leading factor in secondary brain damage following a traumatic brain injury (TBI). Existing therapeutic approaches have limited efficacy against neuroinflammation. The bone marrow, the primary hematopoietic organ, is also a source of inflammatory cells. We propose that targeting the sympathetic regulation of inflammatory cell mobilization could reduce neuroinflammation after TBI. Methods: In ICR mice, we investigated the immune cell response in the blood, bone marrow, motor cortex, and the subventricular zone after TBI modeling and treatment with the sympatholytic agent reserpine. Results: TBI induced neutrophilia and lymphocytosis in the peripheral blood, activated hematopoiesis in the bone marrow, and triggered neuroinflammation and degenerative changes in the cerebral cortex (CC) and the subventricular zone (SVZ) of mice. Reserpine reduced leukocytosis in the blood and hematopoietic activity in the bone marrow of mice with TBI compared to untreated TBI mice. Furthermore, reserpine decreased neutrophilic and lymphocytic infiltration, as well as the number of Iba1+ microglial cells, including M1-polarized microglia, Caspase-3+ cells, and cells expressing myeloperoxidase (MPO) in the CC and SVZ of treated mice. The activity of degenerative processes was also reduced. Additionally, reserpine reduced the number of M2-polarized microglial cells in the SVZ. Conclusions: The sympatholytic drug reserpine may hold promise for the development of a novel approach to treating neuroinflammation and degeneration following a TBI. This is based on its ability to reduce hematopoiesis and mobilize inflammatory cells from the bone marrow into the bloodstream.

13 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
NENatalia Ermakova
Natalia Ermakova
EPEdgar Pan
Edgar Pan
VSVictoria Skurikhina
Victoria Skurikhina
VPValentina Pan
Valentina Pan
IZIrina Zharkikh
Irina Zharkikh
ESEvgenii Skurikhin
Evgenii Skurikhin
Background: Reserpine’s effect on sympathetic regulation of inflammatory cell mobilization and migration reduces neuroinflammation after traumatic brain injury (TBI). We hypothesize that an important consequence of reserpine effect may be the acceleration of brain regenerative processes. Methods: Neuroinflammation and the response of neuronal cells and neural stem cells in the cerebral cortex (CC) and subventricular zone (SVZ) of ICR mice after TBI and reserpine treatment were assessed using histological and immunohistochemical methods. Results: TBI was accompanied by neuroinflammation, cellular and tissue degeneration, neuronal cell damage, and impaired proliferation of neural stem cells in CC and SVZ. Reserpine administration inhibited neuroinflammation and reduced the severity of degenerative processes. Furthermore, an increase in the number of neural stem cells and neuronal cells was observed in the CC and SVZ. Conclusions: Reserpine is a promising compound for developing a new approach to TBI therapy aimed at blocking the sympathetic pathway of neuroinflammation and degeneration. This results in accelerated neuronal cell regeneration.